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Abstract
Many human diseases are characterized by multiple stages of progression. While the typical sequence of disease
progression can be identified, there may be large individual variations among patients. Identifying mean stage durations
and their variations is critical for statistical hypothesis testing needed to determine if treatment is having a significant effect
on the progression, or if a new therapy is showing a delay of progression through a multistage disease. In this paper we
focus on two methods for extracting stage duration statistics from longitudinal datasets: an extension of the linear
regression technique, and a counting algorithm. Both are non-iterative, non-parametric and computationally cheap
methods, which makes them invaluable tools for studying the epidemiology of diseases, with a goal of identifying different
patterns of progression by using bioinformatics methodologies. Here we show that the regression method performs well for
calculating the mean stage durations under a wide variety of assumptions, however, its generalization to variance
calculations fails under realistic assumptions about the data collection procedure. On the other hand, the counting method
yields reliable estimations for both means and variances of stage durations. Applications to Alzheimer disease progression
are discussed.
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Introduction
Many human diseases are characterized by multiple, more or
less well-defined stages of progression. One well-known example is
Alzheimer’s disease (AD) [1], where patients’ cognitive and
functional deterioration follows a progression of several stages
[2,3]. Other diseases that follow a certain pattern of progression,
and can be characterized by several stages, include cancers (such
as multiple myeloma [4,5] and Hodgkin’s disease [6]), HIV [7,8],
lyme disease [9,10], chronic kidney disease [11,12], Parkinson’s
disease [13,14], and many others.
While typical patterns of disease progression can be identified,
there may be large individual variations among patients. Like any
biological variable, rates of disease progression cannot be
described by a fixed ‘‘number’’, but rather come from some
(usually unknown) probability distribution. Fundamental charac-
teristics of these distributions, such as the mean rate of progression
and its variance, can be used as important tools in clinical trials
and disease monitoring. For example, knowing both the mean
duration and the amount of its natural ‘‘spread’’ is essential for
evaluation of treatment efficiency. The group of treated patients
must exhibit an average stage duration which is significantly (that
is, more than a standard deviation) longer than that for the
controls.
Quantitative measurements of the mean and the variance in
stage durations of multi-stage diseases is a difficult empirical and
statistical task. One way to approach it would be following many
patients for the entire disease duration, to record the times when
each new disease stage begins. If information of this kind could be
collected for a sufficient number of patients, then computing the
means and variances of stage durations would be the matter of a
trivial calculation. However, such an approach is often impossible
in real clinical situations. Instead, the patient data collected in
longitudinal studies are usually much more sparse and incomplete.
This means that the mathematical task of extracting the mean and
variance of stage durations becomes much more difficult.
A typical longitudinal patient dataset that logs the individuals’
timing of disease progression consists of dates of the clinician’s
visits and the stages of the disease determined at the time of each
visit. The medical records are often sparse, with only a few visits
per patient, and the timing of the follow-up visits is sporadic. Data
of this kind do not provide stage durations for individual patients.
For example, if a given patient was seen at times t1, t2 and t3, and
was found to be at stages 1, 1, and 3 respectively, then we can say
that for this patient, stage 1 lasted at least t2{t1 years, and stage 2
lasted at most t3{t2 years. In this particular example, we are able
to obtain a lower bound on stage 1 duration and an upper bound
on stage 2 duration. For other cases, even this is impossible. For
example, if we have 2 visits at times t1 and t2 at stages 1 and 2
respectively, all we can say is that the total duration of stages 1 and
2 for this patient was at least t2{t1 years.
In statistics, this type of longitudinal data are referred to as
‘‘censored’’. Extracting information about stage duration distribu-
tions from this type of data is a nontrivial task, and large literature
exists that is devoted to statistical methods in this context [15].
Statistical methods to handle such problems include the regression
method [16], Kaplan-Meier (KM) statistics [17], maximum-
likelihood-based methods described originally by Turnbull
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approaches [22,23]. In addition, a simple counting algorithm
was introduced in [24] to estimate the stage duration cumulative
probability distribution. All types of techniques have advantages
and disadvantages. Here we will focus on two of the above
methods: an extension of the linear regression technique [16,25]
and the counting algorithm. These are by far the simplest methods
of extracting the stage duration means and variances:
N they are non-iterative, so no ‘‘saddle-point’’ solutions can be
observed,
N they are non-parametric, and
N they are computationally very cheap.
The importance of these considerations comes about when one
studies the epidemiology of diseases, and looks for patterns of
disease progression using large patient datasets. Methods of
bioinformatics can be applied to sorting the datasets and
identifying various subgroups of patients with different character-
istics, with a further goal of correlating this with other available
data such as genetic data, demographic data etc. Complex
routines of this kind require estimation of progression statistics for
many subsets of the patient group, to find the meaningful trends.
Therefore, having reliable and very efficient methods for statistical
analysis becomes essential.
The focus of the present analysis is to show that the regression
method performs well for calculating the mean stage durations
under a wide variety of assumptions, however, its generalization to
variance calculations fails under realistic assumptions about the
data collection procedure. On the other hand, the counting
method yields reliable estimates for both means and variances of
stage durations, where the regression method fails. While we will
use AD as the main example for our calculations, this study is
applicable for a wide range of multi-stage diseases.
Example: stages of Alzheimer’s disease
We will illustrate our methodology by using the example of AD.
It has been known for two decades that the rate of progression of
AD varies from patient to patient [26], with illness ranging from a
few years’ duration to as long as 21 years (see [27] and the
references therein). Many factors have been found to be correlated
with the rate of patients’ cognitive deterioration including
apolipoprotein 4 genotype [28,29] and other genetic factors
[30,31], brain atrophy rates [32–34], patterns of regional brain
atrophy [35], ventricular enlargement [36], neuropsychological
and cerebral metabolic profiles [27], vascular factors [37], and
immune system factors [38].
The rate of AD progression can be estimated by using various
cognitive tests, such as the Disability Rating Scale [39], the Mini-
Mental State Examination (MMSE) score[40,41], and Clinical
Dementia Rating (CDR) sum of boxes score [42,43]. Other
measures that have been used are Global Deterioration Scale
(GDS) [44] and its derivative, Functional Assessment Staging
(FAST) [45]. These are reliable assessment techniques for
evaluating functional deterioration in AD patients throughout
the entire course of the illness [46]. They are based on a systematic
examination of the functional changes occurring in patients with
AD, and serve as a strong diagnostic aid for clinicians. The FAST
staging technique has been compared with other scores such as
MMSE, CDR sum of boxes, and others [47], and was found to
correlate with other measures of progression. In a systematic
review of 12 different assessment tools of AD [48], FAST staging
was identified as one of the best studied techniques for reliability,
which shows good to excellent results on intrarater and interrater
reliability.
Although AD is a continuous process, the patient decline usually
follows a number of milestones. FAST staging technique
distinguishes 7 AD stages ranging from 1 (normal adult) to 7
(severe AD). They are further characterized in [16]. The cognitive
and behavioral differences among patients across different stages
are very large, thus making GDS/FAST diagnostics a reliable tool.
In this paper we will apply our statistical tools to a longitudinal
dataset where both FAST and GDS staging systems were applied.
We will focus only on the integer FAST stage values and not on
the FAST substages.
Methods
Data considerations
Data from a longitudinal AD study typically have the following
format [16]. A patient is diagnosed with AD and is seen one or
more times. At each visit, the date of observation and current stage
of AD is recorded according to whatever scale the clinic uses to
track AD progression. Follow-up visits are often conducted at
regular intervals, so that a patient’s record is a sequence of spaced
visits and stage diagnoses. In the absence of knowledge about the
onset date of the current stage, past analyses assume that patients’
first visit and last visit to the clinic occur uniformly within the
current stage [16], so that on average each patient is halfway
through that stage.
One can organize this data in many different ways. A particular
structure which we find useful to impose is that of the transition
class. We consider the set of all patients whose first visit is at stage i
of the disease and whose last visit is at stage j, for iƒj. We call this
subset of patients a transition class. For a disease with K stages
under observation, one can sort the patients into K(Kz1)
2
transition classes. Note that in clinical practice, not all patient
records extend to the final stage of the disease and thus in a clinical
dataset one may expect to find all transition classes with some
patients in them.
Consider a patient with two or more visits to a clinic, whose first
visit is at stage i and last visit is at stage j, with ivj. Then the total
time that patient has been observed, TP, is the sum of the amount
of time the patient has spent in each observed stage:
TP~
X j
k~i
akSk, ð1Þ
where Sk is the duration of stage k. The coefficient ak with k~i or
k~j is a random number distributed in (0,1), and otherwise it
satisfies:
ak~
1, ivkvj,
0, kvi or kwj:
 
We call ak the completion coefficient of stage k. In the absence of
any other information, one might assume that across all patients,
ak are distributed uniformly on (0,1). Thus, on average one might
set all ak~
1
2
and thus generate, for each patient, a single equation
of one or more unknowns, depending on how many stages of the
disease the patient has entered. With enough such patient records,
one can form a large, overdetermined system of equations of N
unknowns, N being the number of stages under observation, and
can solve this system in the least squares sense. This process was
applied without justification in [16].
Data generation method 1: prescribed transition class,
prescribed completion coefficients. We first generate data to
Stage Duration Statistics in Multistage Diseases
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namely that all patients arrive at their first and last visit at the
clinic on average halfway through that stage, and that all transition
classes are populated. To create the dataset, we:
1. Determine the actual timecourse of the disease from a
predetermined set of distributions (one for each stage).
2. We then randomly determine the transition class to which that
patient will belongs.
3. Then, we draw the completion coefficient for the patient’s first
and last visits from a uniform (0,1) distribution.
4. Finally, given this data we can calculate the time from the
patient’s first visit to their last visit and create a patient record
including total time and stages transited.
Theoretical records created by this method can be modified by
changing the assumptions on the distribution of transition classes
(uniform or skewed) and the assumptions on the completion
coefficient (non-uniformly distributed, skewed to favor early or late
visits).
A ‘‘dataset’’ of Np patients created by this method consists of Np
records specifying the transition class (that is, the first and last stage
of visits) and the total time duration between the two visits.
Data generation method 2: prescribed initial stage,
prescribed first completion coefficient, prescribed inter-
office intervals. We next formulate a method to generate test
data for our analysis algorithms which is closer in mechanism to
that which is used in a clinical setting:
1. As before, we specify the actual timecourse of progression for a
patient through all stages of the disease.
2. Choose the stage number for the first visit. For the data sets
used in this paper, the choice of initial stage is weighted
towards earlier stages to ensure population of all possible
transition classes.
3. Calculate the completion coefficient for the first stage. The
initial arrival can be specified to occur at any time during their
current stage; for example, we will employ both a uniform
distribution for completion coefficients and the assumption that
patients tend to first go to the clinic upon recognition of a new
symptom, which occurs at or very near to the beginning of the
current stage.
4. Patients return to the clinic following a loosely prescribed
interval of time (for example, every two years on average). We
draw the time-intervals between consecutive visits from a
distribution. The distributions for inter-office visit times are
given by the sum of 4 random numbers, uniformly distributed
in the range ½0:5,1:5  years (mean of 1 year, standard deviation
of 1=(4
ﬃﬃﬃ
3
p
)&0:14)o r½1:5,2:5  years (mean of 2 years, with the
same standard deviation).
5. For each visit, the patient is evaluated and diagnosed; based on
how much time has elapsed and the true timecourse of the
disease, the patient may or may not have entered into a new
stage.
6. Starting from the second visit, there is a fixed probability (given
by 0:75) for the patient to come back for a subsequent visit, or
to never come back. If a patient’s visit happens after the ‘‘end’’
of the last stage, we disregard this visit and stop the record of
the patient.
A ‘‘dataset’’ of Np patients created by this method consists of Np
records specifying a list of stages at which the patient was seen,
together with the inter-visit time intervals. Such datasets differ
from the ones created by method 1 because each patient may have
more than 2 visits.
Linear regression method for means and variances
We begin by combining the standard linear regression
technique described previously [16] with that of the transition
class. Consider the transition class of all patients starting at stage i
and ending at stage j for iƒj. Then the mean of the total
observation time, T, for all patients in the class is:
E½T ~E½
X j
k~i
akSk ~
X j
k~i
E½akSk ~
X j
k~i
E½ak E½Sk ,
where we have used the tacit assumption from prior work that the
completion coefficients are independent of the stage durations.
Note that if we assume that ak is uniform (0,1) for k~i,j and
ak~1 for ivkvj, then this system becomes:
E½ti,j ~
E½Ti 
2
z
X j{1
s~iz1
E½Ts z
E½Tj 
2
,1 ƒj§iƒN: ð2Þ
This is equivalent to the linear regression scheme described
elsewhere[16]. Herein we have provided a simple justification for
the prior schemes as well as explicitly delineated the assumptions
needed for this method to yield accurate results.
We now turn to the calculation of the variance. As with the
mean, we begin by grouping patient data by transition class.
Under the same assumptions as the mean equations along with an
assumption of independence of each stage duration from one
another, we can calculate:
Var(T)~Var(
X j
k~i
akSk)~
X j
k~i
Var(akSk):
We resolve the variance as follows:
Var(akSk)~E½(akSk)
2 {E2½akSk ~E½a2
k E½S2
k {E2½ak E2½Sk 
~E½a2
k E½S2
k {E½a2
k E2½Sk zE½a2
k E2½Sk {E2½ak E2½Sk 
~E½a2
k Var Sk ðÞ zVar ak ðÞ E2½Sk :
Therefore, if we have information concerning the distribution of
the completion coefficients, then we can write an equation for each
transition class similar to its counterpart in the mean equations:
Var(T)~
X j
k~i
(E½a2
k Var(Sk)zVar(ak)E2½Sk ):
Note that if ivkvj, then ak~1, and so Var(ak)~0. The
variance equations are similar in nature to the means equations
with a necessary adjustment to reflect the variance of the
completion coefficients in the first and last stages of a transition
class. For uniformly distributed completion coefficients, we have
the following system of equations for the variance:
Var½ti,j ~
Var½Ti 
3
z
E2½Ti 
12
z
X j{1
s~iz1
Var½Ts z
Var½Tj 
3
z
E2½Tj 
12
,1 ƒj§iƒN:
ð3Þ
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these equations is the independence of the stage durations of one
another. This assumption will be discussed later in the paper.
To solve these equations, we employ a nonlinear least squares
regression algorithm implemented in MATLAB. We use a
restricted variant of this general algorithm which guarantees
non-negative values for both the mean and variance calculations.
The counting method for means and variances
The counting method first introduced in [24] is somewhat
similar in design to the Kaplan-Meier statistic [17], but exhibits
less bias induced by a coarse sampling methodology which is
common in longitudinal studies of long-term diseases such as AD,
see below.
Unlike the regression method which computes all the stage
durations at once, the counting method considers each stage
separately. For a given stage, say, stage k, we calculate the
numerical cumulative probability distribution of the stage
duration, Pk(t). The method is illustrated in figure 1. We identify
all the patients whose first visit corresponds to stage k as group Gk
patients. For these patients, we assume that their first visit is at
t~0 (the onset of stage k is therefore on average at time t~{~ t t=2).
In figure 1, there are 12 patients diagnosed with stage 1 at time 0.
Consider all the patients in group Gk who visit the doctor’s office
in some relatively short interval Ii~½ti,tiz1 . The interval lengths,
Dti~tiz1{ti, are chosen to ensure that each patient within the
grouping has no more than one visit in the interval. Then we can
compute Ni
t to be the number of patients who, upon visiting the
doctor between times ti and tizDti, transited to the next stage of
the disease. Thus, for all these patients, the duration of stage k was
less that ti. In figure 1, among the 3 patients seen during interval
I1, two remained in stage 1 and one transited to stage 2.
Therefore, we have N1
t ~1. Likewise, we define Ni
s as the number
of patients seen at the clinic in the time interval ½ti,tizDti  who
remained in stage k. For all of these patients, the duration of stage
k is greater than tizDti. For all the patients who have an office
visit in the interval Ii we define ~ t ti to be the mean time of these
office visits, and compute Pk(ti)~
Ni
t
Ni
szNi
t
. The ordered pairs
(~ t ti,Pk(ti)) for i~1:::N are thus a numerical approximation to the
cumulative distribution function, see the bottom panel of figure 1.
We further assume that the underlying probability distribution
has finite support; that is, there exist some tmin for which
tƒtmin[P(t)~0 and tmax for which t§tmax[P(t)~1.W e
specify tmin and tmax as follows: set tmin~floor(t1) and
tmax~ceiling(tM). The choice of interval lengths Dti is somewhat
arbitrary, and defines the discretization grid for the numerical
approximation of the cumulative probability function. We choose
this grid to be non-uniform: we define the time-intervals such that
the number of patients, J, in each of the intervals is the same.
It is important to note here that, as it stands, the counting
method is unable to analyze the final stage in a multistage disease,
as there are no transitions out of the final stage. With sufficiently
accurate information (for example, dates of death for patients in
the study) it may be possible to include the final stage in the
analysis; however, absent that information, we restrict this work to
the first n{1 stages of the disease.
Given the cumulative distribution function derived above, it
becomes a simple calculation to compute the mean and variance
of the underlying distribution. We have:
E½X ~tmax{
X N{1
i~1
Pk(ti)zPk(ti{1)
2
Dti, ð4Þ
Var(X)~(tmax{E½X )
2{
X N{1
i~0
½(~ t ti{E½X )Pk(ti)
z(~ t tiz1{E(X))Pk(tiz1) Dti:
ð5Þ
A more detailed description of the counting method, as well as an
analysis of its properties, is given in Text S1.
Underlying distributions in a 4-stage disease
To begin testing the methods described herein for their ability to
accurately calculate the mean and variance of the underlying
distributions of a multi-stage disease, we first must prescribe some
test distributions. We simulated a 4-stage disease by constructing
three probability distributions for each of the 4 stages. Note that
these probability distributions are not meant to model the real
course of AD or any other disease, but are used as a technique to
test our estimators. For these distribution, the mean stage
durations correspond to the published means for FAST stages
4–7 of AD [49], and the variances are listed in table 1. The three
distributions have different shapes: distribution A is uniform over a
certain time-interval; distribution B is a triangle distribution (the
sum of two uniform distributions), and distribution C is more bell-
shaped and center-concentrated (the sum of four uniform
distributions). Most of the results presented in the figures below
pertain to distribution A, and some results to distribution B. It
turns out that the main findings reported below do not change
with the shape of the distributions.
Results
We first test the methods by using artificial datasets to assess
their validity and reliability under different assumptions. The
Figure 1. A simple illustration of the counting method. We use
the method to approximate the probability distribution of stage 1
duration of a multistage disease. The top panel shows 12 patients’ visits.
The horizontal axis is the time elapsed from stage 1 onset, and the
numbers on top of vertical arrows indicate the stage assessment for
each patient. The time-axis is split into 4 unequal intervals, I1,...,I4,
with J~3 patient visits in each. The corresponding average visit times,
~ t ti, and the numbers of transiting patients, Ni
t, are calculated. In the
bottom panel, the approximation (~ t ti,P1(ti)) is plotted, where
P1(ti)~Ni
t=3.
doi:10.1371/journal.pone.0028298.g001
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we actually know the true ‘‘answer’’ and can compare our
estimates with the correct values. Once the properties of the
statistical methods have been established, we will apply them to a
real-life dataset.
Mean and standard deviation reconstruction via
regression
To study the accuracy of the regression-based method, we adopt
the following strategy. For each total data sample size, Np,w e
randomly generate a large number of datasets (namely, 10,000 for
the examples presented here), and for each such dataset we
calculate the stage means and standard deviations based on
equations. We assume that the number of patients is given by (a)
Np~1,000, (b) Np~10,000, and (c) Np~100,000. The calculated
mean and standard deviation values are then compared with the
true means and standard deviations.
Typical histograms of calculated mean and standard deviation
values are given in figure 2 for the means calculations and figure 3
for the standard deviation calculation. In both figures we used
stage duration distribution A, table [?]. In each panel, the rows
represent different numbers of patients considered, and the
columns correspond to the four stages of the disease. The true
values of the mean and the standard deviations are marked on
each histogram by vertical lines, for comparison.
A convenient measure of accuracy of a method is as follows. The
accuracy of a mean or standard deviation calculation is the length
of the 95% confidence interval centered around the true value of
the mean or standard deviation, respectively. From figures 2 and 3
we note the following trends:
N The histograms for the mean and standard deviation
calculations have a bell-shaped form centered around the true
mean. The spread of the mean and standard deviation
estimates decreases with the number of patients.
Table 1. Test Distributions for AD simulations.
Stage Mean Variance A St. Dev. A Variance B St. Dev. B Variance C St. Dev. C
4 2 3/4 0.87 3/8 0.61 3/16 0.43
5 1.5 1/3 0.58 1/6 0.41 1/12 0.29
6 2.5 4/3 1.16 2/3 0.82 1/3 0.58
7 7 169/12 3.75 169/24 2.65 169/48 1.88
doi:10.1371/journal.pone.0028298.t001
Figure 2. Regression method: the mean stage durations for data generation method 1. Sets of 1,000 (top row), 10,000 (middle row) and
100,000 (bottom row) patients were considered. Each column presents the calculated mean for 10,000 simulations for each stage of a 4-stage disease.
The true mean values are shown by dashed vertical lines.
doi:10.1371/journal.pone.0028298.g002
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number. For all stages, increasing the patient number by a
factor of ten leads to an increase in accuracy by a factor of 3:1
for the mean calculations and by a factor of 2:5 for the
variance calculations.
N At low patient numbers, the standard deviation calculations
are uncertain. A fraction of variances calculated at the 1,000
patient level returned a negative value (these patients are not
shown in the histograms of figure 3). Thus the standard
deviation calculation procedure requires significantly more
data to yield accurate and precise results than does the mean
(see Text S1 for a mathematical explanation of this
observation).
N The accuracy of the first and the last stage mean calculations is
slightly lower than that for middle stages. The reason for that is
the smaller number of transition classes which include the end
stages; for example, there is no transition class which fully
transits the first or the last stage. It is noteworthy that the
difference in accuracy of end stages compared to the middle
stages is not large (less than a factor of 2).
N We have performed calculations for three different distribu-
tions of stage durations (not shown). We observe that the
accuracy of the mean calculations does not depend strongly on
the underlying distribution. The accuracy of the standard
deviation reconstruction is more sensitive to the relative
magnitude of the distribution’s variance (a smaller distribution
variance increases the relative error of reconstruction).
To conclude, we note that, given data which conforms to the
assumptions needed to derive the governing equations, this
method is surprisingly accurate in the calculations of the mean.
Even for small patient samples with a large number of disease
stages (which translates into a very small number of patients per
transition class), we obtain accuracy in the reconstruction on the
order of just a few percent error. However, the variance
reconstruction proves to be much more sensitive to the number
of patients in the sample size than does the mean reconstruction.
With sufficient number of patients per class, it is still possible to
attain accuracy to within 5% error; however, many more patients
are needed in the variance reconstruction than in the mean
reconstruction.
Regression method: non-independent completion
coefficients
We next explore the ability of the linear regression algorithm to
compute the mean and variance of data created by data
generation method 2. We maintain the assumption that patients
initially arrive at the clinic at a random time during their current
stage, and are seen thereafter at time-intervals determined by a
preset distribution. We simulate data sets of 10,000 patients with
disease course determined by distribution set B, with a mean inter-
office interval of 1 year. The results for 1,000 independent runs are
presented for the first stage of the disease in figure 4.
As seen in panels A and B of figure 4, the regression method is
able to accurately recreate neither the means (panel A) nor the
standard deviation (panel B), in sharp contrast to the results from
data generation method 1. Note that the variance values generated
by the algorithm were mostly negative, and they are replaced by
zero values in panel B of figure 4. We next attempt to determine
why the method has failed. Panels C and D of figure 4 show
histograms of the completion coefficients for one particular
realization of a patient dataset, for transition classes 1?2 and
2?3. We can see that in neither of these cases are the completion
coefficients uniformly distributed across the interval ½0,1 .
Figure 3. Regression method: the standard deviation of stage durations. All the parameters are as in figure 1.
doi:10.1371/journal.pone.0028298.g003
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i?iz1 transitions, the distribution of completion coefficients are
not the same, indicating that the assumption that completion
coefficients are independent of the underlying stage distribution is
no longer valid. In fact, the distribution for the 1?2 class appears
to have a peak around the value 0.4, whereas the 2?3 class
appears to be monotonically decreasing across the domain. Given
that this fundamental assumption of the regression method no
longer holds, it is clear that the method cannot give reliable
estimates of stage means or standard deviations.
We next look to determine if the regression method might still
be of some use for data of type 2. Instead of arriving randomly
throughout their current stage, in this new experiment the patients
are assumed to come to their first clinician’ visit at the beginning of
the stage. This is reflected both in the way we generate the
datasets, and in the way we implement the regression algorithm:
all transitions of type i?j, ivj will have an entry coefficient of 1.
This assumption still gives no information about the exit
coefficients nor the single coefficient of i?i transitions, so we will
leave the initial estimate of a value of
1
2
for the mean and
1
3
for the
variance in place. We plot the results of mean and standard
deviation calculation on a 10,000 patient dataset in panels E and F
of figure 4 respectively. We see here that correct knowledge of the
entry coefficient is sufficient to recover most of the accuracy of the
means calculations, but there is still significant error in the
standard deviation calculation.
Thus, we must conclude that, short of extensive knowledge of all
the completion coefficients, the regression technique is in general
only suitable for calculation of the mean stage durations if
N the data is collected in a manner similar to method 1, or
N the data is collected in a manner similar to our method 2,
where patients arrive to their first visit near the onset of the
current stage.
The standard deviation calculations by regression technique are
only reliable in the case (a) above.
Mean and standard deviation reconstruction via the
counting method
We adopt a similar strategy for exploring the accuracy of the
counting method as we did for the regression model. We generate
datasets based upon our three underlying distribution sets and
perform a counting analysis on those sets. This process is repeated
7,500 times so that accuracy statistics may be generated. We
perform these simulations twice, first on a dataset of 1,000
patients, and then on a set of 10,0000 patients. In order for the
counting method to be valid, the patients’ first visit must coincide
with the current stage onset (see the Methods section). Therefore,
to test the counting method we use data generated from procedure
2, which adds another layer of complexity to the analysis. Data
type 2 involves sampling patients at time intervals drawn from a
given distribution. For this test, we consider two such sampling
distributions, one with a mean inter-office visit interval of 1 year
and the other with a mean of 2 years. In other words, in the former
set patients return on average each year for a visit to the clinic,
whereas in the latter set patients come on average every 2 years.
The latter sampling methodology represents a much coarser study,
which is not uncommon in AD longitudinal studies. We will refer
Figure 4. Failure of the regression method to accurately calculate standard deviations in data generation method 2. (A,B). Accuracy
histogram of mean (panel A) and standard deviation (panel B) reconstruction for the first stage of a 4-stage disease using a data set of 10,000 patients
created via method 2 with an inter-office interval mean of 1 year. Entry coefficients were assumed to occur uniformly. (C,D). Actual distribution of
entry-stage completion coefficients for the transition classes 1?2 (panel C) and 2?3 (panel D) for the data in panels A and B. (E,F) Same as in panels
(A,B) but the entry coefficients were assumed to be 1 (patients first visit the clinic at the beginning of their stages). The true values of the mean and
the standard deviations are marked on histograms A, E and F by vertical lines.
doi:10.1371/journal.pone.0028298.g004
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sampling’’ and the other one as the ‘‘coarser sampling’’ case.
We plot representative histograms for the results for distribution
A for sampling intervals of both 1 and 2 years. Figures 5 and 6
show the histograms for mean and standard deviation calculations
for the coarser sampling distribution, which is a more difficult case.
The results for the finer sampling case are presented in Text S1.
The results shown in figures 5 and 6 are striking. Unlike the
regression method, the counting method works very well for type 2
data, both for mean and standard deviation calculation. We do
note that a small bias exists in both the mean and standard
deviation calculations for data sampled at 2 year intervals for
1,000 patients; however, that bias is eliminated with a larger
dataset (see figure 5 and compare row 1 versus row 2, the effect is
most apparent in the left and right columns). This is expected from
our analysis of the counting method, see Text S1. Results for the
counting method can be compared with those for the traditional
KM statistics (Text S1), which suffer from a strong bias in the
context of nonuniform sampling distributions. Unlike the case of
the counting method, this bias is not eliminated by larger sampling
sizes. Thus the counting method can provide accurate and precise
estimates of both stage means and stage standard deviations for a
multistage disease observed in even a coarsely sampled longitu-
dinal study.
We further observe the following trends in the calculations by
the counting method:
N Unlike the regression method, there is no loss of accuracy
(defined in the previous subsection) in the calculation of the
first stage parameters. This is a feature of treating each stage
separately rather than grouping all patients together for a
single calculation.
N However, due to the fact that each stage is treated separately,
the increase in accuracy after increasing the number of
patients by a factor of 10 is less than that observed for the
regression method.
Application to an AD dataset
In order to demonstrate the applicability of the two methods, we
use these techniques to analyze a longitudinal dataset of AD
patients, which is an outcome of a study performed between the
years 1983 and 2006 [25]. The following information is contained
in the dataset: the date of each patient’s visit to the clinic, current
GDS and FAST stage, and some demographic information on
each patient (such as gender, age and years of education). The
total number of AD patients in the dataset is 1321, of which 648
have repeated records (that is, they were seen more than once).
The latter group is the one we considered in this study. The mean
number of records per patient is 2:6+0:9. The patients’ age at the
first visit to the clinic is 73:1+8:7 years. 66% of the patients are
female, and 34% male. The average length of education received
by the patients is 13:1+3:4 years.
In figure 7 we present the inter-visit time distribution, which
shows how long the patients waited before their next visit to the
doctor. Two observations are important. (1) The distribution has a
strong peak around 2 years, and then a weaker mode around 4
years, which tells us that the sampling times are strongly biased.
This is because the patients were instructed to schedule their
subsequent visits after 2 years, see [25]. This results in a highly
Figure 5. Counting method: the mean stage durations for data generation method 2 (the coarse case). Sets of 1,000 (top row) or 10,000
(bottom row) patients were considered. Each column presents the calculated mean for 7,500 simulations for stages 1–3 of a 4-stage disease. The true
mean values are shown by dashed vertical lines.
doi:10.1371/journal.pone.0028298.g005
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reason, a traditional method such as Kaplan Meier would be
strongly compromised, see Text S1. (2) The average inter-visit
time in the dataset is 3:03+1:59, which is comparable with the
approximate average stage duration for GDS/FAST stages 4–6.
For these reasons we conclude that the dataset at hand is most in
line with the data collecting method 2, under the coarse sampling
conditions.
Figure 7. Real-life AD dataset: a strong bias in the sampling distribution.
doi:10.1371/journal.pone.0028298.g007
Figure 6. Counting method: the standard deviation of stage durations. All the parameters are as in figure 4.
doi:10.1371/journal.pone.0028298.g006
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presented in figure 8, see [24] for more information. We plot the
cumulative probability distribution estimated by the counting
method for AD stages 4–6. The mean stage durations and their
standard deviations calculated by this method are provided on top
of the graphs. We further applied the regression method to
calculate the mean stage durations. The results were 2:39 yrs,
1:49, and 2:49 yrs for stages 4, 5 and 6, respectively, see [25]. We
did not attempt to calculate the standard deviations of stage
durations by the regression method because we have established
the method’s poor reliability in this context.
First we note that the graphs of the cumulative probability
distribution approximations (figure 8) have very non-uniform
number of points along the time axes. The striking increase in the
density of points near the 2-yrs mark corresponds to the peak of
the inter-visit time distribution, figure 7. Looking at the results for
the mean values calculated by the two methods, we can see that
they are within the standard deviation of each other, and also
within the standard deviation of the previously reported values,
which are 2 yrs, 1:5 yrs and 2:5 yrs for stages 4, 5, and 6,
respectively [49]. We further notice that the values calculated by
the counting method are somewhat higher than those obtained by
the regression method. This is because for a small number of
patients (see figure 5, top row), there is a certain bias in the
estimates for the mean. This bias can be corrected by increasing
the sampling size.
Finally, we observe that the values of the standard deviations are
very large and are comparable with the mean values. It is true that
these values is a slight overestimation because of the aforemen-
tioned bias which comes with small sampling sizes. However, in
[24], these values were compared with the ones obtained by a
different method (the method of Lagakos [20]), and the results
turned out to be very similar, confirming that the values obtained
by the counting method were valid.
Although before Ref. [24], no values for the standard deviations
of GDS/FAST stage durations of AD had been published, the
magnitude of the calculated values is consistent with the general
notion of AD being a heterogeneous disease [50]. In [51],
inhomogeneity is observed with respect to the rates of ventricle
enlargement, which are related to rates of cognitive decline. Many
papers report a wide spread of progression rates of AD patients
and find different correlates of progression speed. In [52], the
presence of aphasia in AD patients is correlated with a more rapid
course of the disease. Ref. [27] discovers an association between
relatively severe frontal lobe involvement and a rapid clinical
course of AD, measured by using the dementia rating scale and
estimating the symptom duration time. In [53], it is found that the
average rates of decline vary with respect to three types of
measures: a cognitive measure (Alzheimers disease Assessment
Scale-Cognitive Subscale), a functional measure (Physical Self-
Maintenance Scale), and a global measure (CDR sum of boxes).
Although no direct estimate of the variation is presented, these
results clearly show that AD progression rates are heterogeneous in
many respects.
Discussion
In this paper we have presented two different methods which
may be applied to the analysis of multi-stage diseases, where the
goal is to reconstruct the individual stage distribution parameters
(mean and standard deviation). This information is critical for
statistical hypothesis testing needed to determine if an experiment
is having a significant effect on the progression through one or
more stages, e.g. if a new therapy is showing a delay of progression
through a multistage disease. The present study is purely statistical
Figure 8. Application of the counting method to estimating the cumulative probability distributions of AD GDS/FAST durations for
stages 4, 5, and 6 from an AD dataset [25]. The parameter~ t t~0:3 yrs was used. The mean and the standard deviation estimated by this method
are given on top of each figure.
doi:10.1371/journal.pone.0028298.g008
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to develop analytical tools for existing and future patient datasets
in multistage disease with the goal to infer (in the most efficient
and precise way) information about stage durations and their
variations. To this end, we tested two statistical methods and
demonstrated particular situations in which each method might be
applied properly.
The counting method requires more stringent restrictions on the
entry-stage completion coefficients, namely that the onset of a
stage be known as precisely as possible. It, however, makes no
restriction on the exit coefficients. It is also not possible to
reconstruct the parameters of the final stage in the sequence unless
detailed exit data is obtained. Despite these restrictions, this
method gives relatively accurate estimates of both means and
variances even under coarsely sampled data. Thus this method is
most useful for measurements of stage variances, which are critical
for any hypothesis test needed to evaluate treatments, assuming a
sufficiently large patient dataset. This method was used in [24] to
study the statistics of AD progression in a longitudinal patient set.
In particular, it was discovered that GDS and FAST stage
durations of AD patients are characterized by large variances,
confirming the notion of AD being a highly heterogeneous disease
[27,50–53].
Conversely, the regression method is most applicable in
situations where, firstly, the general distribution of the completion
coefficients is known and, secondly, where the data are insufficient
to properly perform the counting method. However, in those
situations, based on our results on the means, calculation may be
trusted at lower numbers of patients if (a) enough information is
available concerning the completion coefficients, and (b) different
stage durations are independent of one another. To see that, recall
that when we derived the equations for the regression method, we
used the assumption of independence of different stages. Care
must be taken when considering the validity of this assumption, as
there are many possible avenues by which it can be broken. For
example, in the AD community there are hypotheses [27,39–
41,54] which concern the presence of different subclasses of
progression speed. That is, there may be sub-populations of
patients in the dataset which progress through each and every
stage at rates drawn from a distribution with a lower mean than
those of other patients. In this case, the stages would only be
conditionally independent from one another, and the equations
will not represent the variances accurately. On the other hand,
given that a patient is in the fast or slow subgroup, the stage
distributions become independent.
Because of these considerations, the regression method is most
useful in searching for partitions within a larger dataset. For
example, several previous reports in the AD literature hypothesize
the presence of fast progressors and slow progressors within the
general AD population [26,27,34]. That is, there are patients
whose AD stage durations are in general shorter than those of their
counterparts across all stages of the disease. A sorting routine, e.g.
based on a genetic algorithm, can be used to partition these
patients into fast progressing versus slow progressing subgroups.
The regression method is the better option to use in such sorting
routines within a defined dataset [25].
In this paper we demonstrated an example of how our
methodology can be applied to studying the stage duration
distributions in AD. In the data set we used, GDS and FAST
staging systems were applied to assess the patients’ decline. Recent
clinical trials involving candidate treatments for AD have targeted
cohorts that already exhibit mild dementia (roughly equivalent to
FAST stage 4). It is generally hypothesized [55] that the failure of
those trials is attributable in large part to enrolling only demented
participants; clinicopathological evidence suggests that even mild
clinical symptoms appear only after AD pathology has advanced
to the point at which neurons are damaged or destroyed.
Therefore, the strongest current focus of AD research is to
identify and treat the early symptomatic and even pre-symptom-
atic stages of the disease (before FAST stage 4), and prevent the
development of significant pathology before ostensibly irreparable
brain damage has occurred [56]. Because these early stages may
last for several years and may have rather poorly-defined borders,
future trials are likely to require more precise measures of
cognitive decline, with greater sensitivity to small cognitive/
behavioral changes. Methods developed in this paper are relevant
to the development of new treatments for AD in the context of
other rating systems with greater sensitivity to detect small changes
in cognition early in the disease. This is the subject of future work.
Supporting Information
Text S1 Details of the methodology developed in the paper.
(PDF)
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